Cargando…

FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes

Cancer cell resistance arises when tyrosine kinase inhibitor (TKI)-targeted therapies induce a drug-tolerant persister (DTP) state with growth via genetic aberrations, making DTP cells potential therapeutic targets. We screened an anti-cancer compound library and identified fibroblast growth factor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Furugaki, Koh, Fujimura, Takaaki, Mizuta, Hayato, Yoshimoto, Takuya, Asakawa, Takashi, Yoshimura, Yasushi, Yoshiura, Shigeki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600219/ https://www.ncbi.nlm.nih.gov/pubmed/37880373 http://dx.doi.org/10.1038/s41698-023-00462-0

Ejemplares similares

Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis
por: Zhang, Jinglin, et al.
Publicado: (2019)

Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
por: Ruan, Ruiwen, et al.
Publicado: (2023)

The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives
por: Santolla, Maria Francesca, et al.
Publicado: (2020)

Differential Specificity of Endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in Complex with KLB
por: Yang, Chaofeng, et al.
Publicado: (2012)

FGF/FGFR signaling in health and disease
por: Xie, Yangli, et al.
Publicado: (2020)

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023)

FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy
por: Quintanal-Villalonga, Álvaro, et al.
Publicado: (2020)

MODL-14. SMALL MOLECULE TARGETING OF ONCOGENIC FGF2-FGFR SIGNALING IN BRAIN TUMORS
por: Kumar, Karthiga Santhana, et al.
Publicado: (2020)

Expression of FGF8, FGF18, and FGFR4 in Gastroesophageal Adenocarcinomas
por: Jomrich, Gerd, et al.
Publicado: (2019)

Oncogenic driver FGFR3-TACC3 is dependent on membrane trafficking and ERK signaling
por: Nelson, Katelyn N., et al.
Publicado: (2018)

FGF19–FGFR4 Signaling in Hepatocellular Carcinoma
por: Raja, Aroosha, et al.
Publicado: (2019)

Expression Atlas of FGF and FGFR Genes in Pancancer Uncovered Predictive Biomarkers for Clinical Trials of Selective FGFR Inhibitors
por: Li, Yuan, et al.
Publicado: (2020)

FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells
por: Yuan, Hong, et al.
Publicado: (2017)

Inhibition of FGFR Signaling by Targeting FGF/FGFR Extracellular Interactions: Towards the Comprehension of the Molecular Mechanism through NMR Approaches
por: Pagano, Katiuscia, et al.
Publicado: (2022)

FGF/FGFR genomic amplification as a predictive biomarker for immune checkpoint blockade resistance: a short report
por: Roussot, Nicolas, et al.
Publicado: (2023)

FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

Osteocyte-Specific Deletion of Fgfr1 Suppresses FGF23
por: Xiao, Zhousheng, et al.
Publicado: (2014)

A Network Map of FGF-1/FGFR Signaling System
por: Raju, Rajesh, et al.
Publicado: (2014)

The Emerging Role of the FGF/FGFR Pathway in Gastrointestinal Stromal Tumor
por: Astolfi, Annalisa, et al.
Publicado: (2020)

FGF/FGFR Pathways in Multiple Sclerosis and in Its Disease Models
por: Rajendran, Ranjithkumar, et al.
Publicado: (2021)

Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
por: Liu, Guihong, et al.
Publicado: (2021)

Roles of the FGF-FGFR Signaling System in Cancer Development and Inflammation
por: Wiedlocha, Antoni, et al.
Publicado: (2021)

Targeting the FGF/FGFR axis and its co-alteration allies
por: Uehara, Y., et al.
Publicado: (2022)

Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity
por: Agrawal, Archita, et al.
Publicado: (2018)

FGFR2-BICC1: A Subtype Of FGFR2 Oncogenic Fusion Variant In Cholangiocarcinoma And The Response To Sorafenib
por: Ying, Xihui, et al.
Publicado: (2019)

Oncogenic FGFR3 gene fusions in bladder cancer
por: Williams, Sarah V., et al.
Publicado: (2013)

Correction: FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

Dual roles of endothelial FGF-2–FGFR1–PDGF-BB and perivascular FGF-2–FGFR2–PDGFRβ signaling pathways in tumor vascular remodeling
por: Hosaka, Kayoko, et al.
Publicado: (2018)

FGFR2-ERC1: A Subtype of FGFR2 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Anlotinib
por: Hong, Chen, et al.
Publicado: (2022)

FGF /FGFR Signal Induces Trachea Extension in the Drosophila Visual System
por: Chu, Wei-Chen, et al.
Publicado: (2013)

FGF23/FGFR4-mediated left ventricular hypertrophy is reversible
por: Grabner, Alexander, et al.
Publicado: (2017)

Landscape of FGF/FGFR Alterations in 12,372 Chinese Cancer Patients
por: Zuo, Wei, et al.
Publicado: (2020)

FGF/FGFR signaling pathway involved resistance in various cancer types
por: Zhou, Yangyang, et al.
Publicado: (2020)

Exploring the FGF/FGFR System in Ocular Tumors: New Insights and Perspectives
por: Loda, Alessandra, et al.
Publicado: (2022)

Interaction of FGF9 with FGFR3‐IIIb/IIIc, a putative driver of growth and aggressive behaviour of hepatocellular carcinoma
por: Paur, Jakob, et al.
Publicado: (2020)

Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230
por: Blackwell, Christina, et al.
Publicado: (2016)

Role of FGF19 induced FGFR4 activation in the regulation of glucose homeostasis
por: Wu, Xinle, et al.
Publicado: (2009)

Antibody-Mediated Activation of FGFR1 Induces FGF23 Production and Hypophosphatemia
por: Wu, Ai-Luen, et al.
Publicado: (2013)

Enterohepatic bacterial infections dysregulate the FGF15-FGFR4 endocrine axis
por: Romain, Guillaume, et al.
Publicado: (2013)

FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib
por: Gao, Lixia, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_q5ukn6kjd9gkoomlcvkku2nf4e